Evidence Snapshot

Butyrylcholinesterase

CHEMBL5077 SINGLE PROTEIN Equus caballus

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T17:56:36Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 2:56 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL5077

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Butyrylcholinesterase as ChEMBL target CHEMBL5077, mapped to UniProt Q9N1N9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Butyrylcholinesterase

SINGLE PROTEIN · Equus caballus

As of 2026-09-13

ChEMBL target ID

CHEMBL5077

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q9N1N9

Carboxylic ester hydrolase

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Butyrylcholinesterase matters

As of 2026-09-13

Butyrylcholinesterase is reviewed as Carboxylic ester hydrolase (UniProt Q9N1N9); the current evidence base includes 12 approved drugs, 581 compounds, and 110 assays, with lead potency reaching pChEMBL 10.0.

Protein context

Carboxylic ester hydrolase

Carboxylic ester hydrolase Sequence length is 602 aa.

Review this target as Butyrylcholinesterase, mapped to UniProt Q9N1N9. ChEMBL maps the protein component as Carboxylic ester hydrolase. Sequence length is 602 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q9N1N9 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 12 approved drugs, 581 compounds, and 110 assays for this target. The dominant activity type is IC50. CHEMBL175949 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL175949 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine

12 approved pChEMBL 10.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Butyrylcholinesterase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9N1N9, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

581

Total Compounds

110

Total Assays

Approved Drugs

IC50: 597.0, KI: 156.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL175949	10.0	Ki	—
No preferred name CHEMBL179192	9.6	Ki	—
No preferred name CHEMBL129108	9.4	Ki	—
No preferred name CHEMBL175555	9.2	Ki	—
No preferred name CHEMBL62084	9.2	IC50	—